×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Is a Surprise Coming for Spero Therapeutics (SPRO) This Earnings Season?
Yahoo News UK
Spero Therapeutics (SPRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into...
16 hours ago
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical...
4 days ago
Investors in Spero Therapeutics (NASDAQ:SPRO) from three years ago are still down 88%, even after 12% gain this past week
Simply Wall St
Spero Therapeutics, Inc. ( NASDAQ:SPRO ) shareholders should be happy to see the share price up 12% in the last...
1 day ago
Spero Therapeutics Delivers On Game Plan To Create Shareholder Value (NASDAQ:SPRO)
Seeking Alpha
Spero Therapeutics, Inc. has continued to build and advance its pipeline over the past several months and is now on the verge of generating...
2 weeks ago
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2023 Earnings Call Transcript
Yahoo Finance
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2023 Earnings Call Transcript March 13, 2024 Spero Therapeutics, Inc. beats earnings expectations.
1 month ago
Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections
GlobeNewswire
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical...
2 months ago
Spero Therapeutics, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Yahoo Finance
After the latest results, the consensus from Spero Therapeutics' twin analysts is for revenues of US$47.8m in 2024, which would reflect a...
1 month ago
Spero Therapeutics Provides Corporate Update and 2024 Outlook
GlobeNewswire
In 2H 2024, expect to provide Phase 2a topline proof-of-concept data from our wholly-owned lead program SPR720 in NTM-PD patients Initiated...
4 months ago
Investors in Spero Therapeutics (NASDAQ:SPRO) have unfortunately lost 90% over the last three years
Yahoo News New Zealand
It's not possible to invest over long periods without making some bad investments. But you want to avoid the really big...
2 days ago
Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Yahoo Finance
Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Stock's On An Uptrend: Are Strong Financials Guiding The Market? ... In this article: SPRO. Most readers...
1 month ago